{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T05:37:51Z","timestamp":1740116271399,"version":"3.37.3"},"publisher-location":"Berlin, Heidelberg","reference-count":219,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"type":"print","value":"9783540344056"},{"type":"electronic","value":"9783540344063"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007]]},"DOI":"10.1007\/978-3-540-34406-3_11","type":"book-chapter","created":{"date-parts":[[2010,5,22]],"date-time":"2010-05-22T10:46:45Z","timestamp":1274525205000},"page":"100-121","source":"Crossref","is-referenced-by-count":0,"title":["Antifungal Therapy in the Intensive Care Unit"],"prefix":"10.1007","author":[{"given":"J. A.","family":"Paiva","sequence":"first","affiliation":[]},{"given":"J. M.","family":"Pereira","sequence":"additional","affiliation":[]}],"member":"297","reference":[{"key":"11_CR1","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/infdis\/167.5.1247","volume":"167","author":"C. Beck-Sague","year":"1993","unstructured":"Beck-Sague C, Jarvis WR (1993) Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980\u20131990. J Infect Dis 167:1247","journal-title":"J Infect Dis"},{"key":"11_CR2","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1128\/CMR.9.4.499","volume":"9","author":"S.K. Fridkin","year":"1996","unstructured":"Fridkin SK, Jarvis WR (1996) Epidemiology of nosocomial fungal infections. Clin Microbiol Rev 9:499","journal-title":"Clin Microbiol Rev"},{"key":"11_CR3","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1001\/jama.1995.03530080055041","volume":"274","author":"J.L. Vincent","year":"1995","unstructured":"Vincent JL, Bihari DJ, Suter PM, et al. (1995) The prevalence of nosocomial infection in intensive care units in Europe (EPIC). JAMA 274:639","journal-title":"JAMA"},{"key":"11_CR4","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1056\/NEJMoa022139","volume":"308","author":"G.S. Martin","year":"2003","unstructured":"Martin GS, Mannino MS, Eaton S, et al. (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 308:1546","journal-title":"N Engl J Med"},{"key":"11_CR5","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/clinids\/20.6.1526","volume":"20","author":"W.R. Jarvis","year":"1995","unstructured":"Jarvis WR (1995) Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 20:1526","journal-title":"Clin Infect Dis"},{"key":"11_CR6","first-page":"512","volume-title":"Wenzel (RP) Prevention and control of nosocomial infections","author":"Pittet","year":"1993","unstructured":"Pittet (1993) Nosocomial blood stream infections. In: Wenzel (RP) Prevention and control of nosocomial infections, 2nd edn. Williams and Wilkins, Baltimore, p 512","edition":"2nd edn."},{"key":"11_CR7","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1001\/archinte.1988.00380120094019","volume":"148","author":"S.B. Wey","year":"1988","unstructured":"Wey SB, Motomi M, Pfaller MA, et al. (1988) Hospital acquired candidemia: the attributable mortality and excess length of stay. Arch Intern Med 148:2642","journal-title":"Arch Intern Med"},{"key":"11_CR8","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S0190-9622(09)80305-8","volume":"28","author":"B.E. Elewski","year":"1993","unstructured":"Elewski BE (1993) Mechanisms of action of systemic antifungal agents. J Am Acad Dermatol 28:S28","journal-title":"J Am Acad Dermatol"},{"key":"11_CR9","first-page":"43","volume-title":"The management of fungal in the ICU","author":"E. Johnson","year":"1999","unstructured":"Johnson E (1999) Mycological activity of antifungal agents. In: Vincent JL (ed) The management of fungal in the ICU. The Liposome Company, London, p 43"},{"key":"11_CR10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/978-3-0348-9146-2_10","volume":"33","author":"P.D. Hoeprich","year":"1989","unstructured":"Hoeprich PD (1989) Chemotherapy for systemic mycosis. Prog Drug Res 33:317","journal-title":"Prog Drug Res"},{"key":"11_CR11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0025-6196(12)60281-X","volume":"67","author":"C.L. Terrell","year":"1992","unstructured":"Terrell CL, Hughes CE (1992) Antifungal agents used for deep-seated mycotic infections. Mayo Clin Proc 67:69","journal-title":"Mayo Clin Proc"},{"key":"11_CR12","first-page":"21","volume-title":"Fungal infections \u2014 diagnosis and management","author":"M.D. Richardson","year":"1997","unstructured":"Richardson MD, Warnock DW (1997) Antifungal drugs. In: Fungal infections \u2014 diagnosis and management, 2nd edn. Blackwell Science, Oxford, p 21","edition":"2nd edn."},{"key":"11_CR13","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/BF00158576","volume":"8","author":"K. Iwata","year":"1992","unstructured":"Iwata K (1992) Drug resistance in human pathogenic fungi. Eur J Epidemiol 8:407","journal-title":"Eur J Epidemiol"},{"key":"11_CR14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.7326\/0003-4819-86-3-319","volume":"86","author":"J.E. Bennett","year":"1977","unstructured":"Bennett JE (1977) Flucytosine. Ann Intern Med 86:319","journal-title":"Ann Intern Med"},{"key":"11_CR15","first-page":"424","volume":"7","author":"J.M. Benson","year":"1988","unstructured":"Benson JM, Nahata MC (1988) Clinical use of systemic antifungal agents. Clin Pharm 7:424","journal-title":"Clin Pharm"},{"key":"11_CR16","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3181\/00379727-138-35943","volume":"138","author":"G. Medoff","year":"1971","unstructured":"Medoff G, Comfort M, Kobayashi GS (1971) Synergistic action of amphotericin B and 5-flucytosine against yeast-like organisms. Proc Soc Exp Biol Med 138:571","journal-title":"Proc Soc Exp Biol Med"},{"key":"11_CR17","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000237987","volume":"27","author":"W.H. Beggs","year":"1981","unstructured":"Beggs WH, Andrews FA, Sarosi GA (1981) Combined action of amphotericin B and 5-flucytosine on pathogenic yeasts susceptible to either drug alone. Chemotherapy 27:247","journal-title":"Chemotherapy"},{"key":"11_CR18","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/clind\/15.6.1003","volume":"15","author":"P. Francis","year":"1992","unstructured":"Francis P, Walsh TJ (1992) Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetic and antifungal therapy. Clin Infect Dis 15:1003","journal-title":"Clin Infect Dis"},{"key":"11_CR19","volume-title":"Care of the surgical patient","author":"E. Anaissie","year":"1994","unstructured":"Anaissie E, Solomkin JS (1994) Fungal infection. In: Willmore DW, Cheung LY, Harken AH (eds) Care of the surgical patient. New York Scientific American Medical 1. American College of Surgeons, New York"},{"key":"11_CR20","first-page":"55","volume-title":"The management of fungal in the ICU","author":"M. Hastings","year":"1999","unstructured":"Hastings M, Wolff M (1999) Current treatment of fungal infections in the ICU. In: Vincent JL (ed) The management of fungal in the ICU. The Liposome Company, London, p55"},{"key":"11_CR21","volume-title":"Therapeutic guidelines in systemic fungal infections","author":"M.D. Richardson","year":"1998","unstructured":"Richardson MD, Kokki M (1998) Therapeutic guidelines in systemic fungal infections. Current Medical Literature, London"},{"key":"11_CR22","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s001340050552","volume":"24","author":"J.L. Vincent","year":"1998","unstructured":"Vincent JL, Anaissie E, Bruining H, et al. (1998) Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Int Care Med 24:206","journal-title":"Int Care Med"},{"key":"11_CR23","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003088-199325040-00006","volume":"25","author":"M. Schafer-Korting","year":"1993","unstructured":"Schafer-Korting M (1993) Pharmacokinetic optimization of oral antifungal therapy. Clin Pharmacokinet 25:329","journal-title":"Clin Pharmacokinet"},{"key":"11_CR24","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/0140-6736(91)93270-J","volume":"35","author":"British Society for Antimicrobial Chemotherapy Working Party on Fungal Infections","year":"1991","unstructured":"British Society for Antimicrobial Chemotherapy Working Party on Fungal Infections (1991) Laboratory monitoring of antifungal chemotherapy. Lancet 35:1577","journal-title":"Lancet"},{"key":"11_CR25","first-page":"71","volume-title":"The management of fungal in the ICU","author":"C. Viscoli","year":"1999","unstructured":"Viscoli C, Castagnola E (1999) Advantages and disadvantages of current therapy. In: Vincent JL (ed) The management of fungal in the ICU. The Liposome Company, London, p 71"},{"key":"11_CR26","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/0002-9343(87)90691-7","volume":"83","author":"A.M. Stamm","year":"1987","unstructured":"Stamm AM, Diasio RB, Dismukes WE, et al. (1987) Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med 83:236","journal-title":"Am J Med"},{"key":"11_CR27","first-page":"642","volume":"33","author":"P. Dellamonica","year":"1985","unstructured":"Dellamonica P, Fournier JP, Garraffo R, et al. (1985) Contribution \u00e0 la surveillance des traitments comportant de la 5-flucytosine. Pathol Biol 33:642","journal-title":"Pathol Biol"},{"key":"11_CR28","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1056\/NEJM197907193010303","volume":"201","author":"J.E. Bennett","year":"1979","unstructured":"Bennett JE, Dismukes WE, Duma RJ, et al. (1979) A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 201:126","journal-title":"N Engl J Med"},{"key":"11_CR29","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1056\/NEJM199401273300407","volume":"330","author":"J.A. Como","year":"1994","unstructured":"Como JA, Dismukes WE (1994) Oral azoles as systemic antifungal therapy. N Engl J Med 330:263","journal-title":"N Engl J Med"},{"key":"11_CR30","first-page":"1799","volume":"36","author":"K.L.M. Lavrijsen","year":"1990","unstructured":"Lavrijsen KLM, van Hout JMG, van Dick DMJ, et al. (1990) Induction potential of fluconazole toward drug-metabolizing enzymes in rat. Antimicrob Agents Chemother 36:1799","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR31","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1128\/AAC.36.9.1799","volume":"36","author":"V. Joly","year":"1992","unstructured":"Joly V, Bolard J, Yeni P (1992) In vitro models for studying toxicity of antifungal agents. Antimicrob Agents Chemother 36:1799","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR32","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1128\/AAC.37.10.2101","volume":"37","author":"H. Bossche van den","year":"1993","unstructured":"van den Bossche H, Marichal P, Le Jeune L, et al. (1993) Effects of itraconazole on cytochrome P450-dependent sterol 14-alpha-demethylation and reduction of 3-ketosteroids in Cryptococcus neoformans. Antimicrob Agents Chemother 37:2101","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR33","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/emboj\/17.2.498","volume":"17","author":"K.M. Kramer","year":"1998","unstructured":"Kramer KM, Tesquet D, Johnson AL, Johnston LH (1998) Budding yeast RSI1\/APC2, a novel gene necessary for initiation of anaphase, encodes an APC subunit. EMBO J 17:498","journal-title":"EMBO J"},{"key":"11_CR34","doi-asserted-by":"crossref","first-page":"658","DOI":"10.2165\/00003495-199550040-00007","volume":"50","author":"K.L. Goa","year":"1995","unstructured":"Goa KL, Barradell LB (1995) Fluconazole \u2014 an update of its pharmacodynamic, pharmacokinetic properties and therapeutic use in major superficial and systemic mycosis in immunocompromised patients. Drugs 50:658","journal-title":"Drugs"},{"key":"11_CR35","doi-asserted-by":"crossref","first-page":"755","DOI":"10.7326\/0003-4819-114-9-755","volume":"114","author":"R.A. Blum","year":"1991","unstructured":"Blum RA, D\u2019Andrea DT, Fiorentino BM, et al. (1991) Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med 114:755","journal-title":"Ann Intern Med"},{"key":"11_CR36","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/infdis\/172.2.599","volume":"172","author":"E.J. Anaissie","year":"1995","unstructured":"Anaissie EJ, Kontoyiannis DP, Huls C, et al. (1995) Safety, plasma concentrations and efficacy of high-dose fluconazole in invasive mould infections. J Infect Dis 172:599","journal-title":"J Infect Dis"},{"key":"11_CR37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.32.1.1","volume":"32","author":"M.S. Saag","year":"1988","unstructured":"Saag MS, Dismukes WE (1988) Azole anti-fungal agents: emphasis on new triazoles. Antimicrob Agents Chemother 32:1","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR38","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1128\/AAC.37.6.1270","volume":"37","author":"A.J. Fischman","year":"1993","unstructured":"Fischman AJ, Alpert NM, Livni E, et al. (1993) Pharmacokinetics of 18 F-labeled fluconazole in healthy human subjects by positron emission tomography. Antimicrob Agents Chemother 37:1270","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR39","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1128\/AAC.28.5.648","volume":"28","author":"M.J. Humphrey","year":"1985","unstructured":"Humphrey MJ, Jevons S, Tarbit MH (1985) Pharmacokinetic evaluation of UK-49858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother 28:648","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR40","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/BF01964056","volume":"8","author":"J.R. Graybill","year":"1989","unstructured":"Graybill JR (1989) New antifungal agents. Eur J Clin Microbiol Infect Dis 8:402","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"11_CR41","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1365-2125.1990.tb03623.x","volume":"29","author":"S. Toon","year":"1990","unstructured":"Toon S, Ross CE, Gokal R, Rowland M (1990) An assessment of the effects of impaired renal function and hemodialysis on the pharmacokinetics of fluconazole. Br J Clin Pharmacol 29:221","journal-title":"Br J Clin Pharmacol"},{"key":"11_CR42","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1086\/444500","volume":"41","author":"R.L. Trotman","year":"2005","unstructured":"Trotman RL, Williamson JC, Shoemaker DM, et al. (2005) Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 41:1159","journal-title":"Clin Infect Dis"},{"key":"11_CR43","first-page":"50","volume-title":"Infection control in the intensive care unit","author":"L. Silvestri","year":"1998","unstructured":"Silvestri L, Mur Laffon D, Gullo A (1998) Antifungal agents. In: van Saene HKF, Silvestri L, de la Cal MA (eds) Infection control in the intensive care unit. Springer, Milan, p 50"},{"key":"11_CR44","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1128\/AAC.32.3.369","volume":"32","author":"R.M. Tucker","year":"1988","unstructured":"Tucker RM, William PL, Arathon EG, et al. (1988) Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis. Antimicrob Agents Chemother 32:369","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR45","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/infdis\/157.1.178","volume":"157","author":"C.A.S. Arndt","year":"1988","unstructured":"Arndt CAS, Walsh TJ, McCully CL, et al. (1988) Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. J Infect Dis 157:178","journal-title":"J Infect Dis"},{"key":"11_CR46","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1128\/AAC.36.3.690","volume":"36","author":"A.J. Berry","year":"1992","unstructured":"Berry AJ, Rinaldi MJ, Graybill JR (1992) Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS. Antimicrob Agents Chemother 36:690","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR47","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/jac\/42.2.253","volume":"42","author":"M.H. Nguyen","year":"1998","unstructured":"Nguyen MH, Yu CY (1998) Voriconazole against fluconazole-susceptible and resistant Candida isolates: in vitro efficacy compared with that of itraconazole and ketoconazole. J Antimicrob Chemother 42:253","journal-title":"J Antimicrob Chemother"},{"key":"11_CR48","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0732-8893(97)00240-X","volume":"31","author":"M.A. Pfaller","year":"1998","unstructured":"Pfaller MA, Jones RN, Messer SAA, et al. (1998) National surveillance of nosocomial bloodstream infections due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn Microbiol Infect Dis 31:327","journal-title":"Diagn Microbiol Infect Dis"},{"key":"11_CR49","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/BF01711909","volume":"20","author":"British Society for Antimicrobial Chemotherapy Working Party on Fungal Infections","year":"1994","unstructured":"British Society for Antimicrobial Chemotherapy Working Party on Fungal Infections (1994) Management of deep Candida infection in surgical and intensive care units. Intensive Care Med 20:522","journal-title":"Intensive Care Med"},{"key":"11_CR50","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1128\/AAC.40.10.2300","volume":"40","author":"D. Sanglard","year":"1996","unstructured":"Sanglard D, Ischer F, Monod M, et al. (1996) Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob Agents Chemother 40:2300","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR51","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/(SICI)1097-0061(19980430)14:6<517::AID-YEA250>3.0.CO;2-D","volume":"14","author":"M.L. Hernaez","year":"1998","unstructured":"Hernaez ML, Gil C, Pla J, et al. (1998) Induced expression of the Candida albicans multidrug resistance gene CDR1 in response to fluconazole and other antifungals. Yeasts 14:517","journal-title":"Yeasts"},{"key":"11_CR52","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1086\/514672","volume":"271","author":"M.H. White","year":"1998","unstructured":"White MH, Bowden RA, Sandler ES, et al. (1998) Randomized, double-blind clinical trial of amphotericin B colloidal dispersion versus amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 271:296","journal-title":"Clin Infect Dis"},{"key":"11_CR53","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1128\/AAC.42.10.2584","volume":"42","author":"K.A. Marr","year":"1998","unstructured":"Marr KA, Lyons CN, Rustad T, et al. (1998) Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR. Antimicrob Agents Chemother 42:2584","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR54","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1128\/AAC.42.7.1819","volume":"42","author":"G.P. Moran","year":"1998","unstructured":"Moran GP, Sanglard D, Donnelly SM, et al. (1998) Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis. Antimicrob Agents Chemother 42:1819","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR55","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1086\/516975","volume":"25","author":"J.A. Bronstein","year":"1997","unstructured":"Bronstein JA, Gros P, Hernandez E, et al. (1997) Fatal acute hepatitis necrosis due to dose-dependent fluconazole hepatotoxicity. Clin Infect Dis 25:1266","journal-title":"Clin Infect Dis"},{"key":"11_CR56","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1001\/archinte.1991.00400050150032","volume":"151","author":"P. Mu\u00f1noz","year":"1991","unstructured":"Mu\u00f1noz P, Moreno S, Berenguer J, et al. (1991) Fluconazole related hepatotoxicity in patients with acquired immunodeficiency syndrome. Arch Intern Med 151:1020","journal-title":"Arch Intern Med"},{"key":"11_CR57","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S0190-9622(08)81838-5","volume":"29","author":"R.J. Hay","year":"1993","unstructured":"Hay RJ (1993) Risk\/benefit of modern antifungal therapy: focus on hepatic reactions. J Am Acad Dermatol 29:S50","journal-title":"J Am Acad Dermatol"},{"key":"11_CR58","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00002018-199818020-00001","volume":"18","author":"E. Albengres","year":"1998","unstructured":"Albengres E, Le Fouet H, Tillement JP (1998) Systemic antifungal agents. Drug Saf 18:83","journal-title":"Drug Saf"},{"key":"11_CR59","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/j.1875-9114.1998.tb03830.x","volume":"18","author":"E.L. Michalets","year":"1998","unstructured":"Michalets EL (1998) Update: clinically significant cytochrome P450 drug interactions. Pharmacotherapy 18:84","journal-title":"Pharmacotherapy"},{"key":"11_CR60","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/AAC.37.4.778","volume":"37","author":"J.A. Barone","year":"1993","unstructured":"Barone JA, Koh JA, Bierman RH, et al. (1993) Food interaction and steady-state pharmacokinetics of itraconazole in healthy male volunteers. Antimicrob Agents Chemother 37:778","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR61","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/00003088-198308010-00002","volume":"8","author":"T.K. Daneshmend","year":"1983","unstructured":"Daneshmend TK, Warnock DW (1983) Clinical pharmacokinetics of systemic antifungal drug. Pharmacokinet 8:17","journal-title":"Pharmacokinet"},{"key":"11_CR62","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1128\/AAC.32.9.1310","volume":"32","author":"T.C. Hardin","year":"1998","unstructured":"Hardin TC, Graybill JR, Fetchick R, et al. (1998) Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 32:1310","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR63","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/jac\/16.1.81","volume":"16","author":"J.R. Perfect","year":"1985","unstructured":"Perfect JR, Savani DV, Durack DT (1985) Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. J Antimicrob Chemother 16:81","journal-title":"J Antimicrob Chemother"},{"key":"11_CR64","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1093\/clinids\/9.Supplement_1.S15","volume":"9","author":"J. Cutsem van","year":"1987","unstructured":"van Cutsem J, van Gerven F, Janssen PA (1987) Activity of orally, topically and parenterally administered itraconazole in the treatment of superficial and deep mycosis: animal models. Rev Infect DIs 9:S15","journal-title":"Rev Infect DIs"},{"key":"11_CR65","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1128\/AAC.37.4.903","volume":"37","author":"J.R. Perfect","year":"1993","unstructured":"Perfect JR, Savani DV, Durack DT (1993) Uptake of itraconazole by alveolar macrophages. Antimicrob Agents Chemother 37:903","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR66","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/BF01962595","volume":"7","author":"T.J. Walsh","year":"1988","unstructured":"Walsh TJ, Pizzo A (1988) Treatment of systemic fungal infections: recent progress and current problems. Eur J Clin Microbiol Infect Dis 7:460","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"11_CR67","first-page":"460","volume":"7","author":"D.W. Denning","year":"1994","unstructured":"Denning DW, Lee JY, Hosteler JS, et al. (1994) NIAID Mycosis Study Group: Multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 7:460","journal-title":"Am J Med"},{"key":"11_CR68","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s005200050129","volume":"6","author":"B.E. Pauw De","year":"1998","unstructured":"De Pauw BE, Meis JF (1998) Progress in fighting systemic fungal infection in hematological neoplasia. Support Cancer Center 6:31","journal-title":"Support Cancer Center"},{"key":"11_CR69","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/jac\/36.5.787","volume":"36","author":"E.M. Johnson","year":"1995","unstructured":"Johnson EM, Davey KG, Szekely A, et al. (1995) Itraconazole susceptibilities of fluconazole susceptible and resistant isolates of five Candida species. J Antimicrob Chemother 36:787","journal-title":"J Antimicrob Chemother"},{"key":"11_CR70","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1128\/JCM.36.7.1886-1889.1998","volume":"36","author":"M.A. Pfaller","year":"1998","unstructured":"Pfaller MA, Jones RN, Doern GV, et al. (1998) International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada and South America for the SENTRY Program. J Clin Microbiol 36:1886","journal-title":"J Clin Microbiol"},{"key":"11_CR71","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0732-8893(97)00192-2","volume":"30","author":"M.A. Pfaller","year":"1998","unstructured":"Pfaller MA, Jones RN, Messer SA, Edmond MB, et al. (1998) National surveillance of nosocomial bloodstream infections due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE program. Diagn Microbiol Infect Dis 30:121","journal-title":"Diagn Microbiol Infect Dis"},{"key":"11_CR72","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0891-5520(02)00068-5","volume":"17","author":"A.H. Groll","year":"2003","unstructured":"Groll AH, Gea-Banacloche JC, Glasmacher A, et al. (2003) Clinical pharmacology of antifungal compounds. Infect Dis Clin North Am 17:159","journal-title":"Infect Dis Clin North Am"},{"key":"11_CR73","unstructured":"Bland SE (2002) Voriconazole. Pharmacotherapy Perspectives Nov\/Dec:32"},{"key":"11_CR74","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/jac\/dkh310","volume":"54","author":"C. Robatel","year":"2004","unstructured":"Robatel C, Rusca M, Padoin C, et al. (2004) Disposition of voriconazole during continuous veno-venous hemodiafiltration in a single patient. J Antimicrob Chemother 54:269","journal-title":"J Antimicrob Chemother"},{"key":"11_CR75","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s100960000395","volume":"19","author":"M.N. Neely","year":"2000","unstructured":"Neely MN, Ghannoum MA (2000) The exciting future of antifungal therapy. Eur J Clin Microbiol Infect Dis 19:897","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"11_CR76","doi-asserted-by":"crossref","first-page":"65S","DOI":"10.1592\/phco.21.11.988.34525","volume":"21","author":"E.J. Ernst","year":"2001","unstructured":"Ernst EJ (2001) Investigational antifungal agents. Pharmacotherapy 21:65S","journal-title":"Pharmacotherapy"},{"key":"11_CR77","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1128\/AAC.44.2.441-443.2000","volume":"44","author":"C.B. Moore","year":"2000","unstructured":"Moore CB, Walls CM, Denning DW (2000) In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B. Antimicrob Agents Chemother 44:441","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR78","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1128\/AAC.43.9.2236","volume":"43","author":"D.J. Diekema","year":"1999","unstructured":"Diekema DJ, Pfaller MA, Messer SA, et al. (1999) In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY antimicrobial surveillance programme in North America and Latin America. Antimicrob Agents Chemother 43:2236","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR79","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1128\/AAC.42.2.313","volume":"42","author":"J.C. Fung-Tome","year":"1998","unstructured":"Fung-Tome JC, Huczko E, Minassian B, et al. (1998) In vitro activity of a new oral triazole: BMS-207147. Antimicrob Agents Chemother 42:313","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR80","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1128\/AAC.40.10.2237","volume":"40","author":"K. Hata","year":"1996","unstructured":"Hata K, Kimura J, Miki H, et al. (1996) In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. Antimicrob Agents Chemother 40:2237","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR81","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1128\/AAC.44.10.2883-2886.2000","volume":"44","author":"T. Yamazumi","year":"2000","unstructured":"Yamazumi T, Pfaller MA, Messer SA, et al. (2000) In vitro activities of ravuconazole against 541 clinical isolates of Cryptococcus neoformans. Antimicrob Agents Chemother 44:2883","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR82","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1128\/AAC.42.12.3242","volume":"42","author":"M.A. Pfaller","year":"1998","unstructured":"Pfaller MA, Messer SA, Hollis RJ, et al. (1998) In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592 and voriconazole. Antimicrob Agents Chemother 42:3242","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR83","unstructured":"Ezzet F, Wexler D, Courtney R, et al. (2001) The pharmacokinetics of posaconazole in neutropenic oncology patients (Abstract A 26). In: Abstracts of 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Edited by American Society for Microbiology, Chicago, p 4"},{"key":"11_CR84","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1128\/CMR.12.1.40","volume":"12","author":"D.J. Sheehan","year":"1999","unstructured":"Sheehan DJ, Hitchcock CA, Sibley CM (1999) Current and emerging azole antifungal agents. Clin Microbiol Rev 12:40","journal-title":"Clin Microbiol Rev"},{"key":"11_CR85","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1128\/AAC.41.10.2310","volume":"41","author":"D. Law","year":"1997","unstructured":"Law D, Moore CB, Denning DW (1997) Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. Antimicrob Agents Chemother 41:2310","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR86","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1128\/AAC.41.2.233","volume":"41","author":"M.A. Pfaller","year":"1997","unstructured":"Pfaller MA, Messer SA, Jones RN (1997) Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob Agents Chemother 41:233","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR87","first-page":"147","volume-title":"Aspergillus and aspergillosis","author":"D. Kerridge","year":"1998","unstructured":"Kerridge D (1998) Polyene macrolides antibiotics. In: van den Bossche H, Mackenzie DWR, Cauwenbergh G (eds) Aspergillus and aspergillosis. Plenum Press, New York, p147"},{"key":"11_CR88","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1128\/AEM.19.6.955-959.1970","volume":"19","author":"B.T. Fields Jr","year":"1970","unstructured":"Fields BT Jr, Bates JH, Abernathy RS (1970) Amphotericin B serum concentrations during therapy. Appl Microbiol 19:955","journal-title":"Appl Microbiol"},{"key":"11_CR89","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1128\/AAC.13.2.271","volume":"13","author":"A.J. Atkinson Jr","year":"1978","unstructured":"Atkinson AJ Jr, Bennett JE (1978) Amphotericin B pharmacokinetics. Antimicrob Agents Chemother 13:271","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR90","first-page":"89","volume-title":"Invasive fungal infections in cancer patients","author":"J.A. Burik van","year":"1995","unstructured":"van Burik JA, Bowden RA (1995) Standard antifungal treatment, including role of alternative modalities to administer amphotericin B. In: Meunier F (ed) Invasive fungal infections in cancer patients. Bailliere Tindall, London, p89"},{"key":"11_CR91","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1128\/AAC.34.3.381","volume":"34","author":"J. Brajtburg","year":"1990","unstructured":"Brajtburg J, Powderly WG, Kobayashi GS, et al. (1990) Amphotericin B delivery systems. Antimicrob Agents Chemother 34:381","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR92","first-page":"371","volume-title":"Candidiasis: pathogenesis, diagnosis and treatment","author":"G.P. Bodey","year":"1991","unstructured":"Bodey GP (1991) Antifungal agents. In: Bodey GP (ed) Candidiasis: pathogenesis, diagnosis and treatment. Raven Press, New York, p 371"},{"key":"11_CR93","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1128\/AAC.46.4.1032-1037.2002","volume":"46","author":"M.A. Pfaller","year":"2002","unstructured":"Pfaller MA, Messer SA, Hollis RJ, et al. (2002) Antifungal activities of posaconazole, ravuconazole and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY antimicrobial surveillance program, 2000. Antimicrob Agents Chemother 46:1032","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR94","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0195-6701(98)90271-7","volume":"38","author":"P.G. Flanagan","year":"1998","unstructured":"Flanagan PG, Barnes RA (1998) Fungal infections in the intensive care unit. J Hosp Infect 38:163","journal-title":"J Hosp Infect"},{"key":"11_CR95","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jac\/36.suppl_B.73","volume":"36","author":"D.W. Warnock","year":"1995","unstructured":"Warnock DW (1995) Fungal complications of transplantations: diagnosis, treatment and prevention. J Antimicrob Chemother 36:73","journal-title":"J Antimicrob Chemother"},{"key":"11_CR96","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1128\/AAC.34.5.906","volume":"34","author":"J.K.S. Chia","year":"1990","unstructured":"Chia JKS, McManus EJ (1990) In vitro tumor necrosis factor induction assay for analysis of febrile toxicity associated with amphotericin B preparations. Antimicrob Agents Chemother 34:906","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR97","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/j.1875-9114.1990.tb02593.x","volume":"10","author":"T.H. Grasela","year":"1990","unstructured":"Grasela TH, Goodwin SD, Walawandu MK, et al. (1990) Prospective surveillance of intravenous amphotericin B use patterns. Pharmacotherapy 10:341","journal-title":"Pharmacotherapy"},{"key":"11_CR98","first-page":"456A","volume":"36","author":"J.A. Gelfand","year":"1988","unstructured":"Gelfand JA, Kimball K, Burke JF, et al. (1988) Amphotericin B treatment of human mononuclear cells in vitro results in secretion of tumour necrosis factor and interleukin-1. Clin Res 36:456A","journal-title":"Clin Res"},{"key":"11_CR99","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/infdis\/161.2.348","volume":"161","author":"A.C. Lin","year":"1990","unstructured":"Lin AC, Goldwasser E, Bernard EM, et al. (1990) Amphotericin B blunts erythropoietin response to anemia. J Infect Dis 161:348","journal-title":"J Infect Dis"},{"key":"11_CR100","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/clinids\/12.2.308","volume":"12","author":"H.A. Gallis","year":"1990","unstructured":"Gallis HA, Drew RH, Pickard WW (1990) Amphotericin B: 30 years of clinical experience. Rev Infect DIs 12:308","journal-title":"Rev Infect DIs"},{"key":"11_CR101","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1001\/archinte.1988.00380110049010","volume":"148","author":"R.A. Branch","year":"1988","unstructured":"Branch RA (1988) Prevention of amphotericin B induced renal impairment: a review on the use of sodium supplementation. Arch Intern Med 148:2389","journal-title":"Arch Intern Med"},{"key":"11_CR102","first-page":"176","volume":"5","author":"T.M. Miano-Mason","year":"1997","unstructured":"Miano-Mason TM (1997) Mechanisms and management of amphotericin B-induced nephrotoxicity. Cancer Pract 5:176","journal-title":"Cancer Pract"},{"key":"11_CR103","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/jac\/33.2.203","volume":"33","author":"S.H. Khoo","year":"1994","unstructured":"Khoo SH, Bond J, Denning DW (1994) Administering amphotericin B: a practical approach. J Antimicrob Chemother 33:203","journal-title":"J Antimicrob Chemother"},{"key":"11_CR104","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/00000658-198202000-00010","volume":"195","author":"J.S. Solomkin","year":"1982","unstructured":"Solomkin JS, Flohr A, Simmons RL (1982) Candida infections in surgical patients: dose requirements and toxicity of amphotericin B. Ann Surg 195:177","journal-title":"Ann Surg"},{"key":"11_CR105","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/clinids\/9.2.403","volume":"9","author":"G. Medoff","year":"1987","unstructured":"Medoff G (1987) Controversial areas of antifungal chemotherapy: short-course and combination therapy with amphotericin B. Rev Infect DIs 9:403","journal-title":"Rev Infect DIs"},{"key":"11_CR106","first-page":"1570","volume":"10","author":"A.C. Laenders","year":"1996","unstructured":"Laenders AC, deMarie S (1996) The use of lipid formulations of amphotericin B for systemic fungal infections. Leukemia 10:1570","journal-title":"Leukemia"},{"key":"11_CR107","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0145-2126(96)00075-6","volume":"21","author":"J. Mehta","year":"1997","unstructured":"Mehta J (1997) Do variations in molecular structure affect the clinical efficacy and safety of lipid-based amphotericin B preparations? Leuk Res 21:183","journal-title":"Leuk Res"},{"key":"11_CR108","first-page":"343","volume":"19","author":"J.R. Wingard","year":"1997","unstructured":"Wingard JR (1997) Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life threatening systemic mycosis. BMT 19:343","journal-title":"BMT"},{"key":"11_CR109","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0272-6386(98)70046-0","volume":"31","author":"R.G. Luke","year":"1998","unstructured":"Luke RG, Boyle JA (1998) Renal effects of amphotericin B lipid complex. Am J Kidney Dis 31:780","journal-title":"Am J Kidney Dis"},{"key":"11_CR110","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1177\/106002809703101011","volume":"31","author":"R. Rap","year":"1998","unstructured":"Rap R, Gubbins PO (1998) Amphotericin B lipid complex. Ann Pharmacother 31:1174","journal-title":"Ann Pharmacother"},{"key":"11_CR111","first-page":"98","volume":"16","author":"C.M. Tang","year":"1997","unstructured":"Tang CM, Bowler ICJW (1997) Do the new lipid formulations of amphotericin B really work? Clin Micro Infect 16:98","journal-title":"Clin Micro Infect"},{"key":"11_CR112","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1086\/514672","volume":"27","author":"M.N. White","year":"1998","unstructured":"White MN, Bowden RA, Sandler ES, et al. (1998) Randomized, double-blind clinical trial of amphotericin B colloidal dispersion versus amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 27:296","journal-title":"Clin Infect Dis"},{"key":"11_CR113","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1086\/516353","volume":"26","author":"T.J. Walsh","year":"1998","unstructured":"Walsh TJ, Hiemenz JW, Seibel NL, et al. (1998) Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 26:1383","journal-title":"Clin Infect Dis"},{"key":"11_CR114","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/tcic.8.4.187.200","volume":"8","author":"J. Garbino","year":"1997","unstructured":"Garbino J, Pittet D (1997) Candida infections in the intensive care unit. Clin Intensive Care 8:187","journal-title":"Clin Intensive Care"},{"key":"11_CR115","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1128\/AAC.41.10.2201","volume":"41","author":"A. Adedoyin","year":"1997","unstructured":"Adedoyin A, Bernard JF, Swenson CE, et al. (1997) Pharmacokinetic profile of Abelcet (amphotericin B lipid complex injection): combined experience from phase I and phase II studies. Antimicrob Agents Chemother 41:2201","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR116","unstructured":"Anaissie E, White M, Uzon O, et al. (1995) Amphotericin B lipid complex versus amphotericin B for the treatment of invasive candidiasis: a prospective randomized, multicenter trial. Programs and abstracts of the 35th Interscience Conference on Antimicrobials Agents and Chemotherapy 30: Abst LM21"},{"key":"11_CR117","unstructured":"Goff DA, Sierawski SJ (1998) A clinical and economic analysis of amphotericin B lipid complex (ABLC; Abelcet) vs. amphotericin B. Programs and abstracts of the 38th Interscience Conference on Antimicrobials Agents and Chemotherapy"},{"key":"11_CR118","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1128\/AAC.35.6.1208","volume":"35","author":"R.M. Fielding","year":"1991","unstructured":"Fielding RM, Smith PC, Wang LH, et al. (1991) Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob Agents Chemother 35:1208","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR119","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1164\/arrd.1982.125.5.610","volume":"125","author":"R.L. Taylor","year":"1982","unstructured":"Taylor RL, Williams DM, Craven PC, et al. (1982) Amphotericin B in liposomes: a novel therapy for histoplasmosis. Am Rev Respir Dis 125:610","journal-title":"Am Rev Respir Dis"},{"key":"11_CR120","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/clinids\/21.5.1145","volume":"21","author":"B.A. Oppenheim","year":"1995","unstructured":"Oppenheim BA, Herbrecht R, Kusne S (1995) The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycosis. Clin Infect Dis 21:1145","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"11_CR121","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000048467","volume":"45","author":"B. Dupont","year":"1999","unstructured":"Dupont B (1999) Clinical efficacy of amphotericin B colloidal dispersion against infections caused by Candida spp. Chemotherapy 45(Suppl 1):27","journal-title":"Chemotherapy"},{"key":"11_CR122","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1128\/AAC.42.3.606","volume":"42","author":"E.J. Anaissie","year":"1998","unstructured":"Anaissie EJ, Mattiuzzi GN, Miller CB, et al. (1998) Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion. Antimicrob Agents Chemother 42:606","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR123","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/BF01575124","volume":"16","author":"R. Herbrecht","year":"1997","unstructured":"Herbrecht R (1997) Safety of amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis 16:74","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"Suppl 1","key":"11_CR124","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000048469","volume":"45","author":"M. Gurwith","year":"1999","unstructured":"Gurwith M, Mamelok R, Pietrelli L, et al. (1999) Renal sparing by amphotericin B colloidal dispersion: clinical experience in 572 patients. Chemotherapy 45(Suppl 1):39","journal-title":"Chemotherapy"},{"key":"11_CR125","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/jac\/28.suppl_B.83","volume":"28","author":"F. Meunier","year":"1991","unstructured":"Meunier F, Prentice HG, Ringden O (1991) Liposomal amphotericin B (Ambisome): safety data from a phase II\/III clinical trial. J Antimicrob Chemother 28:83","journal-title":"J Antimicrob Chemother"},{"key":"11_CR126","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","volume":"340","author":"T.J. Walsh","year":"1999","unstructured":"Walsh TJ, Fingers RW, Arndt CAS, et al. (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Eng J Med 340:764","journal-title":"N Eng J Med"},{"key":"11_CR127","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1592\/phco.19.4.306.30934","volume":"19","author":"D. Slain","year":"1999","unstructured":"Slain D (1999) Lipid-based amphotericin B for the treatment of fungal infections. Pharmacotherapy 19:306","journal-title":"Pharmacotherapy"},{"key":"11_CR128","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1046\/j.1365-2141.1998.00943.x","volume":"103","author":"A.C. Laenders","year":"1998","unstructured":"Laenders AC, Daenen S, Jansen RLH, et al. (1998) Liposomal amphotericin B in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 103:20","journal-title":"Br J Haematol"},{"key":"11_CR129","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1046\/j.1365-2141.1998.00934.x","volume":"103","author":"A.D. Clarck","year":"1998","unstructured":"Clarck AD, Mackenreich S, Tansey PJ, et al. (1998) A comparative analysis of lipid-complexed and liposomal amphotericin B preparations in haematological oncology. Br J Haematol 103:198","journal-title":"Br J Haematol"},{"key":"11_CR130","unstructured":"Holland S, Stone J, Li S, et al. (2001) Effect of hepatic insufficiency on the pharmacokinetics of caspofungin. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy 2001. Edited by American Society for Microbiology, Chicago: Abst A-14"},{"key":"11_CR131","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0140-6736(03)14472-8","volume":"362","author":"D.W. Denning","year":"2003","unstructured":"Denning DW (2003) Echinocandin antifungal drugs. Lancet 362:1142","journal-title":"Lancet"},{"key":"11_CR132","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1086\/323401","volume":"33","author":"A. Villanueva","year":"2001","unstructured":"Villanueva A, Arathoon EG, Noriega LM, et al. (2001) A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 33:1529","journal-title":"Clin Infect Dis"},{"key":"11_CR133","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1128\/AAC.46.2.451-457.2002","volume":"46","author":"E.G. Arathon","year":"2002","unstructured":"Arathon EG, Gotuzzo E, Noriega LM, et al. (2002) Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother 46:451","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR134","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0002-9343(02)01191-9","volume":"113","author":"A. Villanueva","year":"2002","unstructured":"Villanueva A, Gotuzzo E, Arathon EG, et al. (2002) A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 113:294","journal-title":"Am J Med"},{"key":"11_CR135","unstructured":"Holland S, Stone J, Li S, et al. (2001) Drug interactions between caspofungin and tacrolimus. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Edited by American Society for Microbiology, Chicago"},{"key":"11_CR136","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1128\/AAC.44.3.739-746.2000","volume":"44","author":"M. Poeta Del","year":"2000","unstructured":"Del Poeta M, Cruz MC, Cardenas ME, et al. (2000) Synergistic antifungal activities of bafilomycin A(1), fluconazole and the pneumocandin MK-0991\/caspofungin acetate with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrob Agents Chemother 44:739","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR137","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0140-6736(05)67490-9","volume":"366","author":"B.J. Kullberg","year":"2005","unstructured":"Kullberg BJ, Sobel JD, Ruhnke M, et al. (2005) Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidemia in non-neutropenic patients: a randomized non-inferiority trial. The Lancet 366:1435","journal-title":"The Lancet"},{"key":"11_CR138","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/00003246-199804000-00027","volume":"26","author":"S.O. Heard","year":"1998","unstructured":"Heard SO, Fink MP, Gamelli RL, et al. (1998) Effect of prophylactic administration of recombinant human granulocyte colony stimulating factor (filgrastim) on the frequency of nosocomial infections in patients with acute brain injury or cerebral hemorrhage. Crit Care Med 26:748","journal-title":"Crit Care Med"},{"key":"11_CR139","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","volume":"347","author":"J. Mora-Duarte","year":"2002","unstructured":"Mora-Duarte J, Betts R, Rotstein C, et al. (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347:2020","journal-title":"N Engl J Med"},{"key":"11_CR140","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s10096-003-0973-8","volume":"22","author":"A.L. Colombo","year":"2003","unstructured":"Colombo AL, Perfect JR, DiNubile M, et al. (2003) Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 22:470","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"11_CR141","first-page":"130","volume":"25","author":"A. Voss","year":"1996","unstructured":"Voss A, le Noble JL, Verduyn Lunel FM, et al. (1996) Candidemia in intensive care units: risk factors for mortality. Infection 25:130","journal-title":"Infection"},{"issue":"Suppl 1","key":"11_CR142","first-page":"S143","volume":"24","author":"E. Diaz","year":"1998","unstructured":"Diaz E, et al. (1998) Nosocomial candidemia risk factors. Intensive Care Med 24(Suppl 1):S143","journal-title":"Intensive Care Med"},{"key":"11_CR143","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0002-9343(95)00010-0","volume":"100","author":"M.H. Nguyen","year":"1996","unstructured":"Nguyen MH, Peacock JE Jr, Morris AJ, et al. (1996) The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 100:617","journal-title":"Am J Med"},{"key":"11_CR144","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/clinids\/21.4.994","volume":"21","author":"J.H. Rex","year":"1995","unstructured":"Rex JH, Bennett JE, Sugar AM, et al. (1995) Intravascular catheter exchange and duration of candidemia. Clin Infect Dis 21:994","journal-title":"Clin Infect Dis"},{"key":"11_CR145","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/clinids\/20.1.115","volume":"20","author":"J.R. Wingard","year":"1995","unstructured":"Wingard JR (1995) Importance of Candida species other than Candida albicans as pathogens in oncology patients. Clin Infect Dis 20:115","journal-title":"Clin Infect Dis"},{"key":"11_CR146","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1093\/clinids\/14.Supplement_1.S120","volume":"14","author":"F. Meunier","year":"1992","unstructured":"Meunier F, Aoun M, Bitar N (1992) Candidemia in immunocompromised patients. Clin Infect Dis 14:S120","journal-title":"Clin Infect Dis"},{"key":"11_CR147","first-page":"7","volume":"300","author":"W.R. Kirkpatrick","year":"1998","unstructured":"Kirkpatrick WR, Revankar SG, McAtee RK, et al. (1998) Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by Primary CHROMagar Candida screening and susceptibility testing of isolates. J Clin Microbiol 300:7","journal-title":"J Clin Microbiol"},{"key":"11_CR148","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1001\/archsurg.1997.01430350034006","volume":"132","author":"D.B. Safran","year":"1997","unstructured":"Safran DB, Dawson E (1997) The effect of empiric and prophylactic treatment with fluconazole on yeast isolates in a surgical trauma intensive care unit. Arch Surg 132:1184","journal-title":"Arch Surg"},{"key":"11_CR149","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1128\/JCM.27.2.236-240.1989","volume":"27","author":"R.J. Blinkhorn","year":"1989","unstructured":"Blinkhorn RJ, Adelstein D, Spagnuolo PJ (1989) Emergence of a new opportunistic pathogen, Candida lusitaniae. J Clin Microbiol 27:236","journal-title":"J Clin Microbiol"},{"key":"11_CR150","doi-asserted-by":"crossref","unstructured":"Warnock DW, Burke JF, Cope NJ, et al. (1988) Fluconazole resistance in Candida glabrata. Lancet 1310","DOI":"10.1016\/S0140-6736(88)92919-4"},{"key":"11_CR151","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/archsurg.1997.01430350047008","volume":"132","author":"T.G. Gleason","year":"1997","unstructured":"Gleason TG, May AK, Caparelli D, et al. (1997) Emerging evidence of selection of fluconazole-tolerant fungi in surgical intensive care units. Arch Surg 132:1197","journal-title":"Arch Surg"},{"key":"11_CR152","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1128\/AAC.36.12.2602","volume":"36","author":"H. Bossche van den","year":"1992","unstructured":"van den Bossche H, Marichal P, Odds FC, et al. (1992) Characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother 36:2602","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR153","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1086\/514731","volume":"28","author":"C. Viscoli","year":"1999","unstructured":"Viscoli C, Girmenia C, Marinus A, et al. (1999) Candidemia in cancer patients: a prospective, multicenter surveillance study by the invasive fungal infection group of the EORTC. Clin Infect Dis 28:1071","journal-title":"Clin Infect Dis"},{"key":"11_CR154","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1056\/NEJM199110313251803","volume":"325","author":"J.R. Wingard","year":"1991","unstructured":"Wingard JR, Merz WG, Rinaldi MG, et al. (1991) Increase in Candida krusei infection among patients with BMT and neutropenia treated prophylactically with fluconazole. N Engl J Med 325:1274","journal-title":"N Engl J Med"},{"key":"11_CR155","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/infdis\/147.1.116","volume":"147","author":"S.M. Seidenfeld","year":"1983","unstructured":"Seidenfeld SM, Cooper BH, Smith JW, et al. (1983) Amphotericin B tolerance: a characteristic of Candida parapsilosis not shared by other Candida species. J Infect Dis 147:116","journal-title":"J Infect Dis"},{"key":"11_CR156","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1128\/JCM.20.6.1194-1195.1984","volume":"20","author":"W.G. Merz","year":"1984","unstructured":"Merz WG (1984) Candida lusitaniae: frequency of recovery, colonization, infection and amphotericin B resistance. J Clin Microbiol 20:1194","journal-title":"J Clin Microbiol"},{"key":"11_CR157","first-page":"131","volume":"5","author":"B.D. Fisher","year":"1999","unstructured":"Fisher BD, Dixon DM (1999) Invasive aspergillosis: progress in early diagnosis and treatment. Am J Med 5:131","journal-title":"Am J Med"},{"key":"11_CR158","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/BF00156818","volume":"1989","author":"T.J. Walsh","year":"1989","unstructured":"Walsh TJ, Dixon DM (1989) Nosocomial aspergillosis: environmental microbiology, hospital epidemiology, diagnosis and treatment. Eur J Epidemiol 1989:131","journal-title":"Eur J Epidemiol"},{"key":"11_CR159","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1086\/516480","volume":"175","author":"A. Wald","year":"1997","unstructured":"Wald A, Leisenring W, van Burik JA, et al. (1997) Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 175:1459","journal-title":"J Infect Dis"},{"key":"11_CR160","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1086\/517672","volume":"26","author":"J. Rello","year":"1998","unstructured":"Rello J, Esandi ME, Mariscal D, et al. (1998) Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: report of eight cases and review. Clin Infect Dis 26:1473","journal-title":"Clin Infect Dis"},{"key":"11_CR161","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1128\/JCM.28.7.1616-1622.1990","volume":"28","author":"T.J. Walsh","year":"1990","unstructured":"Walsh TJ, Melcher GP, Rinaldi MG, et al. (1990) Trichosporum beigelii, an emerging pathogen resistant to amphotericin B. B J Clin Microbiol 28:1616","journal-title":"B J Clin Microbiol"},{"key":"11_CR162","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/0002-9343(76)90141-8","volume":"61","author":"L.I. Lutwick","year":"1976","unstructured":"Lutwick LI, Galgiani JN, Johnson RH, et al. (1976) Visceral fungal infections due to Pseudallescheria boydii. In vitro drug sensitivity studies. Am J Med 61:632","journal-title":"Am J Med"},{"key":"11_CR163","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1056\/NEJM199202273260903","volume":"326","author":"H. Gastinne","year":"1992","unstructured":"Gastinne H, Wolff M, Delatour F, Faurisson F, et al. (1992) A controlled trial in intensive care units of selective decontamination of the digestive tract with nonabsorbable antibiotics. The French Group on selective decontamination of the digestive tract. N Engl J Med 326:594","journal-title":"N Engl J Med"},{"key":"11_CR164","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1378\/chest.109.3.765","volume":"109","author":"B. Quinio","year":"1996","unstructured":"Quinio B, Albanese J, Bues-Charbit M, et al. (1996) Selective decontamination of the digestive tract in multiple trauma patients. A prospective, double-blind, randomized, placebo-controlled study. Chest 109:762","journal-title":"Chest"},{"key":"11_CR165","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1086\/514504","volume":"25","author":"J.E. Edwards Jr","year":"1997","unstructured":"Edwards JE Jr, Bodey GP, Bowden RA, et al. (1997) International conference for the development of a consensus on the management and prevention of severe Candida infections. Clin Infect Dis 25:43","journal-title":"Clin Infect Dis"},{"key":"11_CR166","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/clinids\/18.1.77","volume":"18","author":"M.P. Dub\u00e9","year":"1994","unstructured":"Dub\u00e9 MP, Heseltine PNR, Rinaldi MG, et al. (1994) Fungemia and colonization with nystatin resistant Candida rugosa in a burn unit. Clin Infect Dis 18:77","journal-title":"Clin Infect Dis"},{"key":"11_CR167","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1086\/515200","volume":"28","author":"J.S. Burket","year":"1999","unstructured":"Burket JS, Bartlett RH, Hyde KV, et al. (1999) Nosocomial infections in adult patients undergoing extracorporeal membrane oxygenation. Clin Infect Dis 28:828","journal-title":"Clin Infect Dis"},{"key":"11_CR168","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/00002480-199510000-00010","volume":"41","author":"D.J. Goldstein","year":"1995","unstructured":"Goldstein DJ, El-Amir NG, Ashton RCJ, et al. (1995) Fungal infections in left ventricular assist device recipients. ASAID J 41:873","journal-title":"ASAID J"},{"key":"11_CR169","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1097\/00003246-199906000-00019","volume":"27","author":"P. Eggimann","year":"1999","unstructured":"Eggimann P, Francioli P, Bille J, et al. (1999) Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 27:1066","journal-title":"Crit Care Med"},{"key":"11_CR170","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","volume":"346","author":"T.J. Walsh","year":"2002","unstructured":"Walsh TJ, Pappas P, Winston DJ, et al. (2002) Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346:225","journal-title":"N Engl J Med"},{"key":"11_CR171","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","volume":"351","author":"T.J. Walsh","year":"2004","unstructured":"Walsh TJ, Teppler H, Donowitz GR, et al. (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351:1391","journal-title":"N Engl J Med"},{"key":"11_CR172","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1093\/clinids\/20.6.1531","volume":"20","author":"R.P. Wenzel","year":"1995","unstructured":"Wenzel RP (1995) Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 20:1531","journal-title":"Clin Infect Dis"},{"key":"11_CR173","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0891-5520(05)70363-9","volume":"11","author":"W.L. Wright","year":"1997","unstructured":"Wright WL, Wenzel RP (1997) Nosocomial candida: Epidemiology, transmission and prevention. Infect Dis Clin North Am 11:411","journal-title":"Infect Dis Clin North Am"},{"key":"11_CR174","first-page":"11","volume-title":"Management of fungal in the ICU","author":"J. Rello","year":"1999","unstructured":"Rello J, Diaz E (1999) Epidemiology and aetiology of fungal infections in the ICU. In: Vincent JL (ed) Management of fungal in the ICU. The Liposome Company, London, p11"},{"key":"11_CR175","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1097\/00000658-199412000-00008","volume":"230","author":"D. Pittet","year":"1994","unstructured":"Pittet D, Monod M, Suter PM, et al. (1994) Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 230:751","journal-title":"Ann Surg"},{"key":"11_CR176","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s001340050334","volume":"23","author":"M.G. Petri","year":"1997","unstructured":"Petri MG, Konig J, Moecke HP, et al. (1997) Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients. Intensive Care Med 23:317","journal-title":"Intensive Care Med"},{"key":"11_CR177","doi-asserted-by":"crossref","first-page":"511","DOI":"10.7326\/0003-4819-67-3-511","volume":"67","author":"C.A. Ellis","year":"1967","unstructured":"Ellis CA, Spivack ML (1967) The significance of candidemia. Ann Intern Med 67:511","journal-title":"Ann Intern Med"},{"key":"11_CR178","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1001\/archinte.1970.00310120045004","volume":"126","author":"P. Toala","year":"1970","unstructured":"Toala P, Schroeder SA, Daly AK, et al. (1970) Candida at Boston City Hospital. Clinical and epidemiological characteristics and susceptibility to eighth antimicrobial agents. Arch Intern Med 126:983","journal-title":"Arch Intern Med"},{"key":"11_CR179","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/clind\/15.3.414","volume":"15","author":"V.J. Fraser","year":"1992","unstructured":"Fraser VJ, Jones M, Dunkel J, et al. (1992) Candidemia in a tertiary care hospital: epidemiology, risk factors and predictors of mortality. Clin Infect Dis 15:414","journal-title":"Clin Infect Dis"},{"key":"11_CR180","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1056\/NEJM199104113241511","volume":"324","author":"J.E. Edwards Jr","year":"1991","unstructured":"Edwards JE Jr (1991) Invasive Candida infections \u2014 evolution of a fungal pathogen. N Engl J Med 324:1060","journal-title":"N Engl J Med"},{"key":"11_CR181","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/clinids\/23.5.964","volume":"23","author":"E. Anaissie","year":"1996","unstructured":"Anaissie E, Darouiche RO, Abi-Said D, et al. (1996) Management of invasive Candida infections: results of a prospective randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 23:964","journal-title":"Clin Infect Dis"},{"key":"11_CR182","first-page":"170","volume":"101","author":"E.J. Anaissie","year":"1996","unstructured":"Anaissie EJ, Vartivarian SE, Abi-Said D, et al. (1996) Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Clin Infect Dis 101:170","journal-title":"Clin Infect Dis"},{"key":"11_CR183","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1001\/archinte.1995.00430220087009","volume":"155","author":"M.H. Nguyen","year":"1995","unstructured":"Nguyen MH, Peacock JE Jr, Tanner DC, et al. (1995) Therapeutic approaches in patients with candidemia. Evaluation in a multicenter prospective observational study. Arch Intern Med 155:2429","journal-title":"Arch Intern Med"},{"key":"11_CR184","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1056\/NEJM199411173312001","volume":"331","author":"J.H. Rex","year":"1994","unstructured":"Rex JH, Bennett JE, Sugar AM, et al. (1994) A randomized trial comparing fluconazole and amphotericin B for the treatment of candidemia in patients with neutropenia. N Engl J Med 331:1325","journal-title":"N Engl J Med"},{"key":"11_CR185","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/BF01591361","volume":"15","author":"J.W. Wout vant","year":"1996","unstructured":"van\u2019t Wout JW (1996) Fluconazole treatment of candidal infections caused by non-albicans Candida species. Eur J Clin Microbiol Infect Dis 15:238","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"11_CR186","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1093\/clinids\/17.4.662","volume":"17","author":"B.S.P. Ang","year":"1993","unstructured":"Ang BSP, Telenti A, King B, et al. (1993) Candidemia from a urinary tract source: microbiological aspects and clinical significance. Clin Infect Dis 17:662","journal-title":"Clin Infect Dis"},{"key":"11_CR187","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0924-8579(99)00031-X","volume":"11","author":"J.D. Sobel","year":"1999","unstructured":"Sobel JD (1999) Management of asymptomatic candiduria. Int J Antimicrob Agents 11:285","journal-title":"Int J Antimicrob Agents"},{"key":"11_CR188","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000283074","volume":"59","author":"I. Potasman","year":"1997","unstructured":"Potasman I, Castin A, Moskovitz B, et al. (1997) Oral fluconazole for Candida urinary tract infection. Urol Int 59:252","journal-title":"Urol Int"},{"key":"11_CR189","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/00005373-199308000-00020","volume":"35","author":"Z. Nassoura","year":"1993","unstructured":"Nassoura Z, Ivatury RR, Simon RJ, et al. (1993) Candidemia as an early marker of disseminated infection in the critically surgical patient: the role of fluconazole therapy. Trauma 35:290","journal-title":"Trauma"},{"key":"11_CR190","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/clinids\/20.1.183","volume":"20","author":"J.F. Fisher","year":"1995","unstructured":"Fisher JF, Newman CL, Sobel JD (1995) Yeasts in the urine: solution for a budding problem. Clin Infect Dis 20:183","journal-title":"Clin Infect Dis"},{"key":"11_CR191","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/clinids\/20.5.1152","volume":"20","author":"H.S. Leu","year":"1995","unstructured":"Leu HS, Huang CT (1995) Clearance of funguria with short-course anti-fungal regimens: prospective, randomized, controlled study. Clin Infect Dis 20:1152","journal-title":"Clin Infect Dis"},{"key":"11_CR192","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1093\/ajhp\/56.9.872","volume":"56","author":"S.A. Nerbit","year":"1999","unstructured":"Nerbit SA, Katz LE, McClain BW, et al. (1999) Comparison of two concentrations of amphotericin B bladder irrigation in the treatment of funguria in patients with indwelling urinary catheters. Am J Health Syst Pharm 56:872","journal-title":"Am J Health Syst Pharm"},{"key":"11_CR193","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s10096-003-1014-3","volume":"22","author":"L. Ostrosky-Zeichner","year":"2003","unstructured":"Ostrosky-Zeichner L, Oude Lashof AML, Kullberg BJ, et al. (2003) Voriconazole salvage treatment of invasive candididasis. Eur J Clin Microbiol Infect Dis 22:651","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"11_CR194","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0163-4453(93)92761-K","volume":"26","author":"W. Graninger","year":"1992","unstructured":"Graninger W, Presterie E, Schneeweiss B, et al. (1992) Treatment of Candida albicans fungemia with fluconazole. J Infect 26:133","journal-title":"J Infect"},{"key":"11_CR195","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1046\/j.1439-0507.1999.00269.x","volume":"42","author":"L. Pittrow","year":"1999","unstructured":"Pittrow L, Penk A (1999) Dosage adjustments of fluconazole during continuous renal replacement therapy (CAVH, CVVH, CAVHD, CVVHD). Mycosis 42:17","journal-title":"Mycosis"},{"key":"11_CR196","first-page":"499","volume":"28","author":"S.B. Moody","year":"1993","unstructured":"Moody SB, Sveska KJ (1993) Fluconazole dosing in renal impairment: a drug usage evaluation. Hosp Formul 28:499","journal-title":"Hosp Formul"},{"key":"11_CR197","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0002-9343(91)90005-I","volume":"91","author":"C.A. Kaufman","year":"1991","unstructured":"Kaufman CA, Bradley SE, Ross SC, et al. (1991) Hepatosplenic candidiasis. Successful treatment with fluconazole. Am J Med 91:137","journal-title":"Am J Med"},{"key":"11_CR198","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/0002-9343(91)90006-J","volume":"91","author":"E.J. Anaissie","year":"1991","unstructured":"Anaissie EJ, Bodey GP, Kantarjian H, et al. (1991) Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 91:142","journal-title":"Am J Med"},{"key":"11_CR199","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S0891-5520(20)30714-5","volume":"9","author":"S. Hadley","year":"1995","unstructured":"Hadley S, Karchmer AW(1995) Fungal infections in solid organ transplant recipients. Infect Dis Clin North Am 9:1045","journal-title":"Infect Dis Clin North Am"},{"issue":"Suppl 1","key":"11_CR200","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1093\/clinids\/19.Supplement_1.S33","volume":"19","author":"P.L. Hibberd","year":"1994","unstructured":"Hibberd PL, Rubin RH (1994) Clinical aspects of fungal infection in organ transplant recipients. Clin Infect Dis 19(Suppl 1):S33","journal-title":"Clin Infect Dis"},{"key":"11_CR201","first-page":"964","volume-title":"Yearbook of intensive care and emergency medicine","author":"D. Pittet","year":"1996","unstructured":"Pittet D, Anaissie E, Solomkin JS (1996)When to start antifungal therapy in the non-neutropenic critically ill patient. In: Vincent JL (ed) Yearbook of intensive care and emergency medicine. Springer-Verlag, Berlin, p 964"},{"issue":"Suppl 2","key":"11_CR202","first-page":"41","volume":"41","author":"A. Penk","year":"1998","unstructured":"Penk A, Pittrow L (1998) Status of fluconazole in the therapy of endogenous Candida endophthalmitis. Mycosis 41(Suppl 2):41","journal-title":"Mycosis"},{"key":"11_CR203","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1439-0507.1993.tb00749.x","volume":"36","author":"A. Palacio del","year":"1993","unstructured":"del Palacio A, Cuetara MS, Ferro M, et al. (1993) Fluconazole in the management of endophthalmitis in disseminated candidiasis of heroin addicts. Mycosis 36:193","journal-title":"Mycosis"},{"key":"11_CR204","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/clinids\/20.3.657","volume":"20","author":"M.E. Akler","year":"1995","unstructured":"Akler ME, Velland M, McNealy DM, et al. (1995) Use of fluconazole in the treatment of Candida endophthalmitis. Clin Infect Dis 20:657","journal-title":"Clin Infect Dis"},{"key":"11_CR205","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1128\/AAC.35.2.288","volume":"35","author":"S.G. Filler","year":"1991","unstructured":"Filler SG, Cusllip MA, Mayer CL, et al. (1991) Comparison of fluconazole and amphotericin B for the treatment of disseminated candididasis and endophthalmitis in rabbits. Antimicrob Agents Chemother 35:288","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR206","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1128\/AAC.31.1.6","volume":"31","author":"D.V. Savani","year":"1987","unstructured":"Savani DV, Perfect JR, Cobo LM, et al. (1987) Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob Agents Chemother 31:6","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR207","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/clinids\/17.5.888","volume":"17","author":"J. Nomura","year":"1993","unstructured":"Nomura J, Ruskin J (1993) Failure of therapy with fluconazole for Candida endophthalmitis. Clin Infect Dis 17:888","journal-title":"Clin Infect Dis"},{"key":"11_CR208","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3109\/08982109309150729","volume":"3","author":"J.P. Adler-Moore","year":"1993","unstructured":"Adler-Moore JP, Profitt RT (1993) Development, characterization, efficacy and modes of action of (Ambisome) a unicellular liposomal formulation of amphotericin B. J Liposomal Res 3:429","journal-title":"J Liposomal Res"},{"key":"11_CR209","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1086\/514704","volume":"27","author":"A. Wong-Beringer","year":"1998","unstructured":"Wong-Beringer A, Jacobs RA, Guglielmo BJ (1998) Lipid formulation of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 27:603","journal-title":"Clin Infect Dis"},{"key":"11_CR210","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","volume":"347","author":"R. Herbrecht","year":"2002","unstructured":"Herbrecht R, Denning DW, Patterson TF, et al. (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408","journal-title":"N Engl J Med"},{"key":"11_CR211","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jinf.2004.05.011","volume":"50","author":"N.A. Kartsonis","year":"2005","unstructured":"Kartsonis NA, Saah AJ, Lipka CJ, et al. (2005) Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J Infect 50:196\u2013205","journal-title":"J Infect"},{"key":"11_CR212","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s00520-003-0522-0","volume":"11","author":"F.S. Taccone","year":"2003","unstructured":"Taccone FS, Marechal L, Meuleman N, et al. (2003) Caspofungin salvage therapy in a neutropenic patient with probable invasive aspergillosis: a case report. Support Cancer Center 11:742","journal-title":"Support Cancer Center"},{"key":"11_CR213","unstructured":"Maertens JA, et al. (2002) Caspofungin for aspergillosis (intolerant or refractory). In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Edited by American Society for Microbiology, Chicago"},{"key":"11_CR214","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1439-0507.1994.tb00301.x","volume":"37","author":"M. Scheven","year":"1994","unstructured":"Scheven M, Senf L (1994) Quantitative determination of fluconazole-amphotericin B antagonism for Candida albicans by agar-diffusion. Mycosis 37:205","journal-title":"Mycosis"},{"key":"11_CR215","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1128\/AAC.39.3.598","volume":"19","author":"A.M. Sugar","year":"1995","unstructured":"Sugar AM, Hitchcock CA, Troke PF, Picard M (1995) Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B. Antimicrob Agents Chemother 19:598","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR216","first-page":"1834","volume":"187","author":"V. Petraitis","year":"2003","unstructured":"Petraitis V, Petraitiene R, Sarafandi AA, et al. (2003) Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. Clin Infect Dis 187:1834","journal-title":"Clin Infect Dis"},{"key":"11_CR217","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1086\/423380","volume":"39","author":"K.A. Marr","year":"2004","unstructured":"Marr KA, Boeckh M, Carter RA, et al. (2004) Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 39:797","journal-title":"Clin Infect Dis"},{"key":"11_CR218","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/S0161-6420(94)31175-4","volume":"101","author":"S.P. Donahue","year":"1994","unstructured":"Donahue SP, Greven CM, Zuravleff JJ, et al. (1994) Intraocular candidiasis in patients with candidemia: clinical implications derived from a prospective multicenter study. Ophthalmology 101:1302","journal-title":"Ophthalmology"},{"key":"11_CR219","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/myc.1990.33.6.283","volume":"33","author":"M. Eiff von","year":"1990","unstructured":"von Eiff M, Fahrenkamp A, Roos N, Fegeler W, vande Loo J (1990) Hepatosplenic candidiasis \u2014 a late manifestation of Candida septicemia. Mycosis 33:283","journal-title":"Mycosis"}],"container-title":["Infectious Diseases in Critical Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-540-34406-3_11.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T02:06:20Z","timestamp":1740103580000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-540-34406-3_11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007]]},"ISBN":["9783540344056","9783540344063"],"references-count":219,"URL":"https:\/\/doi.org\/10.1007\/978-3-540-34406-3_11","relation":{},"subject":[],"published":{"date-parts":[[2007]]}}}